Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
16.42
+0.39 (2.43%)
Oct 28, 2025, 4:00 PM EDT - Market closed
Edgewise Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts that cover Edgewise Therapeutics stock have a consensus rating of "Buy" and an average price target of $37.9, which forecasts a 130.82% increase in the stock price over the next year. The lowest target is $14 and the highest is $51.
Price Target: $37.9 (+130.82%)
Analyst Consensus: Buy
* Price targets were last updated on Sep 25, 2025.
Analyst Ratings
The average analyst rating for Edgewise Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 2 | 2 | 2 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Initiates $20 | Hold | Initiates | $20 | +21.80% | Sep 25, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $40 → $30 | Buy | Maintains | $40 → $30 | +82.70% | Aug 19, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $48 → $49 | Buy | Maintains | $48 → $49 | +198.42% | Aug 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $42 | Strong Buy | Initiates | $42 | +155.79% | Jun 30, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $48 | Buy | Reiterates | $48 | +192.33% | Jun 5, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
2.32M
EPS This Year
-1.64
from -1.45
EPS Next Year
-2.01
from -1.64
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 26.3M | |||
| Avg | n/a | 2.3M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.60 | -1.80 | |||
| Avg | -1.64 | -2.01 | |||
| Low | -1.64 | -2.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.